{"id":"W3201876104","doi":"10.1016/j.ejca.2021.08.023","title":"Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"Medac; PharmaMar; Deutsche Krebshilfe; Eisai; European Commission; Chugai Pharmaceutical; Seagen; F. Hoffmann-La Roche; Incyte; Mersana Therapeutics; Karyopharm Therapeutics; Clovis Oncology; Deutsche Forschungsgemeinschaft; GlaxoSmithKline; Takeda Oncology; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Olaparib; Bevacizumab; Medicine; Hazard ratio; Oncology; Placebo; Internal medicine; Population; Ovarian cancer; Cancer; Confidence interval; Chemotherapy; Pathology; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01020469,0.001604202,0.00272817,0.0006943601,0.0001678556,0.0008807757,0.0008557694,0.0009777937,0.003420587],"category_scores_gemma":[0.01138971,0.0004866061,0.005751244,0.0005019129,0.0007447525,0.000793461,0.0008359338,0.002004991,0.0002167436],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007155256,"about_ca_system_score_gemma":0.0009421199,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004999368,"about_ca_topic_score_gemma":0.0009180173,"domain_scores_codex":[0.9903778,0.007790934,0.0004414479,0.0006682852,0.0004724717,0.0002490702],"domain_scores_gemma":[0.9932235,0.004086312,0.001699277,0.0004243919,0.0002159355,0.0003505605],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.943387,0.0007826872,0.005107677,0.001493192,0.02935224,0.00004400968,0.00007953915,0.002153531,0.001437195,0.0004933584,0.0004264047,0.01524317],"study_design_scores_gemma":[0.6747048,0.1975946,0.0406967,0.0004350203,0.06988492,0.0002443009,0.00011747,0.006203868,0.003342349,0.002296982,0.004363179,0.0001159392],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.976652,0.01265248,0.003318805,0.0003301347,0.00033986,0.002301042,0.001613114,0.0000643817,0.002728044],"genre_scores_gemma":[0.99142,0.001294868,0.002616215,0.0003076577,0.0001179125,0.002155757,0.001220246,0.00001473378,0.0008525485],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01020469,"threshold_uncertainty_score":0.05396819,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1338717010028006,"score_gpt":0.4275435263922756,"score_spread":0.2936718253894749,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}